S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

$824.84
+1.46 (+0.18%)
(As of 09/22/2023 08:52 PM ET)
Compare
Today's Range
$818.30
▼
$831.50
50-Day Range
$719.01
▼
$844.37
52-Week Range
$668.00
▼
$847.50
Volume
464,600 shs
Average Volume
590,809 shs
Market Capitalization
$89.54 billion
P/E Ratio
21.80
Dividend Yield
N/A
Price Target
$899.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
9.1% Upside
$899.67 Price Target
Short Interest
Healthy
1.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
0.89mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$27.23 M Sold Last Quarter
Proj. Earnings Growth
2.60%
From $35.42 to $36.34 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

399th out of 962 stocks

Pharmaceutical Preparations Industry

175th out of 454 stocks

See Top Rated MarketRank™ Stocks Here

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Price History

REGN Stock News Headlines

September 23, 2023 | finance.yahoo.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 40% Below Their Intrinsic Value Estimate
September 23, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Cantor Fitzgerald
September 25, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
September 22, 2023 | finance.yahoo.com
Top Stock Reports for Amazon.com, Boeing, Regeneron & Others
September 21, 2023 | markets.businessinsider.com
Analyst Expectations for Regeneron Pharmaceuticals's Future
September 20, 2023 | msn.com
Regeneron’s Eylea HD Gets FDA Approval, Boosting Company’s Growth Outlook
September 20, 2023 | finance.yahoo.com
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
September 19, 2023 | seekingalpha.com
Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
September 25, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
September 17, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $920.00 by Analysts at Argus
September 17, 2023 | americanbankingnews.com
Argus Raises Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $920.00
September 17, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Research Coverage Started at Westpark Capital
September 17, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Westpark Capital
September 15, 2023 | msn.com
Argus Research Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation
September 15, 2023 | msn.com
WestPark Capital Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold Recommendation
September 11, 2023 | seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
September 11, 2023 | seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
September 11, 2023 | forbes.com
Is Regeneron Stock Fully Valued At $820?
September 11, 2023 | msn.com
Regeneron Pharmaceuticals Chief Financial Officer to Retire in February
September 8, 2023 | finance.yahoo.com
Regeneron Announces Updates to Board of Directors
September 8, 2023 | finance.yahoo.com
Regeneron Provides Update on Planned Chief Financial Officer Transition
September 6, 2023 | seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 2023 Wells Fargo Healthcare Conference (Transcript)
September 5, 2023 | benzinga.com
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today
August 31, 2023 | finance.yahoo.com
Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD
August 29, 2023 | benzinga.com
Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy
August 22, 2023 | benzinga.com
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development
August 22, 2023 | finance.yahoo.com
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
CIK
872589
Web
www.regeneron.com
Phone
(914) 847-7000
Fax
914-347-2113
Employees
11,851
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$899.67
High Stock Price Forecast
$1,050.00
Low Stock Price Forecast
$650.00
Forecasted Upside/Downside
+9.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
27 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$37.83
Trailing P/E Ratio
21.80
Forward P/E Ratio
23.29
P/E Growth
2.45
Net Income
$4.34 billion
Net Margins
33.93%
Pretax Margin
37.69%
Return on Equity
19.19%
Return on Assets
14.94%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
5.45
Quick Ratio
4.64

Sales & Book Value

Annual Sales
$12.17 billion
Price / Sales
7.36
Cash Flow
$44.54 per share
Price / Cash Flow
18.52
Book Value
$207.31 per share
Price / Book
3.98

Miscellaneous

Outstanding Shares
108,560,000
Free Float
98,973,000
Market Cap
$89.54 billion
Optionable
Optionable
Beta
0.19

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Leonard S. Schleifer M.D.Dr. Leonard S. Schleifer M.D. (Age 70)
    Ph.D., Co-Founder, Pres, CEO & Co-Chairman
    Comp: $7M
  • Dr. George D. Yancopoulos M.D. (Age 63)
    Ph.D., Co-Founder, Pres, Chief Scientific Officer & Co-Chairman
    Comp: $6.59M
  • Mr. Robert E. Landry Jr.Mr. Robert E. Landry Jr. (Age 59)
    Exec. VP of Fin. & CFO
    Comp: $1.84M
  • Dr. Andrew J. Murphy Ph.D. (Age 64)
    Exec. VP of Research
    Comp: $1.62M
  • Mr. Daniel P. Van Plew (Age 50)
    Exec. VP and GM of Industrial Operations & Product Supply
    Comp: $1.95M
  • Ms. Marion E. McCourtMs. Marion E. McCourt (Age 63)
    Exec. VP of Commercial
    Comp: $1.5M
  • Ms. Patrice Gilooly
    Sr. VP of Quality Assurance & Operations
  • Mr. Christopher R. Fenimore CPAMr. Christopher R. Fenimore CPA (Age 52)
    Sr. VP, Head of Accounting & Controller
  • Mr. Gerald Underwood
    Sr. VP of Technical Operations
  • Mr. Bob McCowan
    Sr. VP of IT & Chief Information Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

27 Wall Street research analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $650.00 to $1,050.00. On average, they anticipate the company's stock price to reach $899.67 in the next year. This suggests a possible upside of 9.1% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN stock has increased by 14.3% and is now trading at $824.84.
View the best growth stocks for 2023 here.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our REGN earnings forecast.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported $10.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.48 by $1.76. The biopharmaceutical company earned $3.16 billion during the quarter, compared to analysts' expectations of $3.02 billion. Regeneron Pharmaceuticals had a net margin of 33.93% and a trailing twelve-month return on equity of 19.19%. The firm's revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $9.77 EPS.
Read the conference call transcript.

What ETFs hold Regeneron Pharmaceuticals' stock?

ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), Subversive Mental Health ETF (SANE) and 2ndVote Life Neutral Plus ETF (LYFE).

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (67.91%), BlackRock Inc. (8.28%), Capital World Investors (5.06%), State Street Corp (4.60%), Capital International Investors (2.69%) and Geode Capital Management LLC (2.08%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $824.84.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $89.54 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $37.83 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 11,851 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -